![Pharvaris N.V. logo](/logos/PHVS.webp)
Pharvaris N.V.
NASDAQ:PHVS
Overview | Financials
Company Name | Pharvaris N.V. |
Symbol | PHVS |
Currency | USD |
Price | 19.12 |
Market Cap | 1,032,627,224 |
Dividend Yield | 0% |
52-week-range | 15 - 33 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Berndt Axel Edvard Modig CPA, M.B.A., MBA |
Website | https://pharvaris.com |
An error occurred while fetching data.
About Pharvaris N.V.
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD